POEMS Syndrome: A Rare and Complex Blood Disorder – Symptoms, Causes, and Treatment of this Hematological Condition

POEMS Syndrome is a rare and multisystemic hematological condition, characterized by a constellation of clinical manifestations that include polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes. This complex plasma cell dyscrasia, with an estimated incidence of 0.3 cases per 100,000 people, predominantly affects adults between 40 and 60 years of age. Its pathogenesis involves abnormal proliferation of plasma cells and overproduction of vascular endothelial growth factor (VEGF), leading to a cascade of systemic effects.

In this article, we will explore in detail the etiology, clinical presentation, diagnostic methods, and current therapeutic options for POEMS syndrome, offering a comprehensive perspective on this exceptional and challenging hematological condition.

What is POEMS syndrome?

POEMS syndrome is a rare blood disorder that affects multiple body systems. Its name is an acronym describing the main manifestations of the condition: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein (M-protein), and Skin changes. According to the medical definition, this complex condition is considered a plasma cell dyscrasia, meaning it involves abnormal production of plasma cells in the bone marrow.

Polyneuropathy, one of the defining characteristics of POEMS syndrome, manifests as progressive muscle weakness and abnormal sensations in the extremities. Organomegaly, on the other hand, involves enlargement of organs such as the liver, spleen, or lymph nodes. Endocrinopathy refers to dysfunctions of the endocrine glands, which can affect the production of essential hormones.

The M-protein, or monoclonal protein, is an abnormal protein produced by malignant plasma cells. Finally, skin changes can include hyperpigmentation, skin thickening, or excessive hair growth.

POEMS syndrome – incidence and possible causes

As mentioned earlier, POEMS syndrome is a rare disease, with an estimated incidence of about 0.3 cases per 100,000 people. It typically affects adults aged between 40 and 60 years, being slightly more common in men than in women. Although the exact cause remains unknown, research suggests that elevated levels of vascular endothelial growth factor (VEGF) play a crucial role in the pathogenesis of the disease.

It is important to understand that POEMS syndrome is part of a broader group of rare hematological disorders known as plasma cell dyscrasias. These diseases are characterized by abnormal production of plasma cells and monoclonal proteins. In the specific case of POEMS syndrome, there is a close link with other hematological conditions, particularly Castleman disease. Moreover, approximately 11-30% of patients with POEMS syndrome also have Castleman disease, a rare lymphoproliferative disorder that can complicate diagnosis and treatment.

[cta_produs style=”style_1″ product=”468759″ image=”https://aronia-charlottenburg.com/wp-content/uploads/2025/03/Ce-este-sindromul-POEMS_-Lipozomal-Curcumin.jpg”]

In POEMS syndrome, chronic inflammation and oxidative stress are essential factors that worsen symptoms and contribute to progressive deterioration of health. Curcumin, the main bioactive compound of turmeric (Curcuma longa), is known for its anti-inflammatory, antioxidant, and immunomodulatory properties, making it a promising candidate as an adjuvant in managing pathological processes associated with this syndrome.

POEMS syndrome – the role of curcumin in reducing inflammation

One of the relevant mechanisms by which curcumin can influence the progression of POEMS syndrome is by inhibiting inflammatory pathways mediated by NF-κB and pro-inflammatory cytokines such as IL-6 and TNF-α. These molecules play a key role in amplifying systemic inflammation, and their blockade can reduce symptom severity. Additionally, through its antioxidant properties, curcumin helps neutralize free radicals, thereby protecting affected tissues, including peripheral nerves, which are severely impacted in POEMS syndrome.

Another important aspect is its effect on the cardiovascular system, potentially improving vascular function and reducing the risk of edema and pulmonary hypertension, which are common in this condition. Curcumin has also been studied for its ability to regulate angiogenesis, a process involved in the abnormal proliferation of blood vessels characteristic of patients with POEMS syndrome.

A major challenge in using curcumin is its low bioavailability, which limits its absorption and therapeutic efficacy. For this reason, advanced forms, such as Liposomal Curcumin, offer significant advantages, allowing for up to 99% absorption and optimized distribution in the body. This technology protects the active substance from rapid degradation in the liver, ensuring more effective action on tissues affected by inflammation and oxidative stress.

Although curcumin is not a curative treatment for POEMS syndrome, its introduction as a complementary therapy, under medical supervision, can help reduce inflammation, protect the nervous system, and support vascular function, thereby improving patients’ quality of life.

Causes and pathophysiology of POEMS syndrome

The exact causes of POEMS syndrome remain largely unknown, but recent research has provided new insights into the pathophysiological mechanisms involved in this complex condition. At the root of the disease is an abnormal proliferation of plasma cells, a type of immune system cell responsible for antibody production. These abnormal plasma cells produce excessive amounts of monoclonal protein, particularly of the lambda type, which can form deposits in tissues and cause inflammation and organ dysfunction.

Vascular endothelial growth factor (VEGF) plays a central role in the pathogenesis of POEMS syndrome. Elevated VEGF levels are a defining characteristic of the disease and contribute to many of its clinical manifestations. VEGF stimulates angiogenesis (the formation of new blood vessels), increases vascular permeability, and contributes to endothelial dysfunction. In other words, these effects explain many of the symptoms observed in POEMS syndrome, such as edema, pleural effusions, and ascites.

Polyneuropathy, a key manifestation of POEMS syndrome, results from demyelination and axonal degeneration of peripheral nerves. This process is likely caused by the toxic effects of overproduced cytokines, as well as VEGF-induced microangiopathy. Organomegaly and skin changes are also related to the effects of VEGF and other cytokines on the respective tissues. Endocrinopathy, another important component of the syndrome, arises from hypothalamic-pituitary dysfunction and the direct effects of cytokines on endocrine glands.

Symptoms and clinical manifestations of POEMS syndrome

POEMS syndrome is characterized by a wide range of symptoms and clinical manifestations, reflecting its multisystemic nature.

Primarily, polyneuropathy, one of the defining features of the disease, typically manifests as progressive muscle weakness and abnormal sensations in the extremities. It usually begins in the feet and progresses upwards, potentially affecting the upper limbs later. Furthermore, the severity of neuropathy can vary considerably from one patient to another and can significantly impact mobility and quality of life.

Photo source: Shutterstock.com

Organomegaly, another important characteristic, involves the enlargement of organs such as the liver, spleen, or lymph nodes. This can often be asymptomatic, being discovered only during imaging examinations.

In contrast, endocrinopathy in POEMS syndrome can affect multiple endocrine glands, leading to a variety of symptoms. These may manifest as erectile dysfunction or amenorrhea, hypothyroidism, diabetes mellitus, or adrenal insufficiency. Skin manifestations are also diverse and can include diffuse hyperpigmentation, hypertrichosis (excessive hair growth), skin thickening, and nail changes.

Last but not least, other common clinical manifestations are peripheral edema, pleural effusions, and ascites, all related to increased vascular permeability induced by VEGF. Patients may also experience constitutional symptoms such as fever, fatigue, and weight loss. Sclerotic bone lesions are another important characteristic, although these may be asymptomatic and discovered only on imaging investigations. However, the clinical manifestations of POEMS syndrome can vary significantly from one patient to another, both in terms of the type and severity of symptoms.

Diagnosis of POEMS syndrome

Diagnosing POEMS syndrome can be challenging due to the rarity of the disease and its multisystemic nature. To establish the diagnosis, physicians use a combination of clinical and paraclinical criteria.

The diagnostic criteria updated in 2011 include two mandatory criteria: the presence of polyneuropathy and a monoclonal gammopathy (usually lambda type). In addition to these, at least one of the major criteria must be present: sclerotic bone lesions, Castleman disease, or elevated VEGF levels.

The investigations required to confirm the diagnosis are complex and multidisciplinary. These include nerve conduction studies and electromyography to assess neuropathy, serum and urine protein electrophoresis to detect monoclonal protein, and determination of serum VEGF levels. Imaging plays an important role, including bone X-rays, CT, or MRI to identify sclerotic lesions, and PET-CT to assess disease extent. Bone marrow biopsy and aspirate are essential for excluding other plasma cell dyscrasias.

The differential diagnosis of POEMS syndrome is based on the analysis of several conditions with similar clinical presentations, such as chronic inflammatory demyelinating polyneuropathy (CIDP), multiple myeloma, or AL amyloidosis. It is crucial to differentiate between these diseases, as therapeutic approaches can be significantly different.

Treatment of POEMS syndrome

The treatment of POEMS syndrome requires a multidisciplinary and personalized approach, tailored to each individual patient. Generally, the main treatment goals are to reduce the proliferation of abnormal plasma cells, lower VEGF levels, and relieve symptoms. Furthermore, therapeutic options are based on systemic therapies, stem cell transplantation, and local treatments for bone lesions.

Beyond theoretical considerations, systemic therapies are usually the first line of treatment and may include chemotherapy, corticosteroids, and immunomodulatory agents. Regimens based on melphalan, cyclophosphamide, or bortezomib are commonly used. Corticosteroids, particularly high-dose dexamethasone, are often administered in combination with chemotherapy. Immunomodulatory agents such as lenalidomide or thalidomide have proven effective in reducing VEGF levels and improving symptoms.

For eligible patients, autologous hematopoietic stem cell transplantation can provide long-term remission. This procedure involves high-dose chemotherapy to eliminate abnormal plasma cells, followed by the infusion of the patient’s own stem cells. Although a promising therapeutic option, transplantation requires careful patient selection and rigorous post-procedure monitoring.

Photo source: Shutterstock.com

Prognosis and evolution of POEMS syndrome

Despite the severity of this hematological disease, the prognosis of POEMS syndrome has significantly improved in recent years. This progress is due to advances in diagnosis and treatment. The overall median survival is currently estimated at over 10 years from diagnosis. The 5-year survival rate is approximately 60-70% of cases. Moreover, patients who benefit from autologous stem cell transplantation tend to have better survival rates. In some studies, 5-year survival reaches up to 90%.

Factors influencing prognosis are diverse. They are related to the stage of the disease at diagnosis, the severity of neuropathy, and serum VEGF levels. The response to initial treatment also has a significant impact. Patients diagnosed and treated in early stages tend to have better outcomes. Close monitoring of treatment response is essential. This includes regular clinical evaluation, monitoring of serological markers such as VEGF and monoclonal protein, and periodic imaging studies.

However, long-term management of POEMS syndrome presents significant challenges. Firstly, there is a risk of relapse even after achieving remission, requiring continuous monitoring. The side effects of intensive treatments can have long-term consequences. Lastly, neuropathy recovery can be slow and incomplete, requiring long-term rehabilitation.

POEMS syndrome – advances in treatment and perspectives

Despite these challenges, the outlook for patients with POEMS syndrome is continuously improving, thanks to ongoing research and the development of new therapeutic strategies.

In conclusion, POEMS syndrome remains a significant challenge in the field of hematology, requiring a multidisciplinary approach to diagnosis and treatment. Thanks to medical advancements and recent progress in understanding the disease’s pathogenesis, particularly the central role of VEGF, new therapeutic perspectives have opened up.

However, many unknown aspects of POEMS syndrome still require further research. The development of more specific biomarkers for diagnosis and disease monitoring, as well as the identification of new therapeutic targets, are important research directions.

In the future, a more personalized treatment approach, based on each patient’s genetic and molecular profile, is anticipated. Thus, next-generation immunomodulatory therapies and potential gene therapies offer hope for better disease control and improved quality of life for patients with POEMS syndrome.

References:

1. Dispenzieri, A. (2019). POEMS syndrome: 2019 Update on diagnosis, risk-stratification, and management. American Journal of Hematology, 94(7), 812-827;
2. Nasu, S., Misawa, S., Sekiguchi, Y., Shibuya, K., Kanai, K., Fujimaki, Y., … & Kuwabara, S. (2012). Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, Neurosurgery & Psychiatry, 83(5), 476-479;
3. Li, J., & Zhou, D. B. (2019). New advances in the diagnosis and treatment of POEMS syndrome. British Journal of Haematology, 185(4), 594-605;
4. Keddie, S., D’Sa, S., Foldes, D., Carr, A. S., Reilly, M. M., & Lunn, M. P. (2018). POEMS neuropathy: optimising diagnosis and management. Practical Neurology, 18(4), 278-290;
5. Dispenzieri, A., & Buadi, F. K. (2013). A review of POEMS syndrome. Oncology, 27(12), 1242-1250;
6. Suichi, T., Misawa, S., Beppu, M., Takahashi, S., Sekiguchi, Y., Shibuya, K., … & Kuwabara, S. (2019). Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology, 93(10), e975-e983;
7. Wang, C., Huang, X. F., Cai, Q. Q., Cao, X. X., Duan, M. H., & Cai, H. (2017). Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome. Leukemia, 31(1), 100-106.

Photo source: Shutterstock.com